Effect of Dilatation and Curettage on the Endometrial Receptivity

January 26, 2020 updated by: Mohamed S Sweed, MD, Ain Shams University

Effect of Dilatation and Curettage on the Endometrial Receptivity and Pregnancy Outcome in Patients With Recurrent Implantation Failure

Effect of dilatation and curettage on the endometrial receptivity and pregnancy outcome in patients with recurrent implantation failure

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt
        • Ain shams university maternity hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. All the patients had at least 3 failed trials of IVF-ET with day 5 fresh blastocyst transferred
  2. At least 10 high-grade embryos were obtained in the previous trials
  3. Level of AMH more than or equal 1.1 ng/ml.
  4. Age: Less than or equal to 35 years

Exclusion Criteria:

  1. Patients with uterine pathology e.g. myoma , Asherman syndrome, Septum ,adenomyosis
  2. Hydrosalpinx
  3. Endometriosis
  4. patients with diagnosed autoimmune diseases affecting pregnancy e.g. S.L.E.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: D&C
Procedure: D&C
Dilatation and curettage
Procedure: ICSI
Intra Cytoplasmic Sperm Injection
Other: No D&C
Procedure: ICSI
Intra Cytoplasmic Sperm Injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Live Birth Rate
Time Frame: 9 months
9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ain Shams University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 31, 2018

Primary Completion (Actual)

November 1, 2019

Study Completion (Actual)

December 10, 2019

Study Registration Dates

First Submitted

March 26, 2018

First Submitted That Met QC Criteria

March 27, 2018

First Posted (Actual)

April 2, 2018

Study Record Updates

Last Update Posted (Actual)

January 28, 2020

Last Update Submitted That Met QC Criteria

January 26, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AS1764

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Embryo Implantation

Clinical Trials on D&C

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe